BPDCN
MCID: BLS007
MIFTS: 46

Blastic Plasmacytoid Dendritic Cell (BPDCN)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Blastic Plasmacytoid Dendritic Cell

MalaCards integrated aliases for Blastic Plasmacytoid Dendritic Cell:

Name: Blastic Plasmacytoid Dendritic Cell 53
Blastic Plasmacytoid Dendritic Cell Neoplasm 53 59 73
Lymphoblastoid Variant of Nk-Cell Lymphoma 53 59
Cd4+/cd56+ Hematodermic Neoplasm 53 59
Monomorphic Nk-Cell Lymphoma 53 59
Blastic Nk-Cell Lymphoma 53 59
Bpdcn 53 59

Characteristics:

Orphanet epidemiological data:

59
cd4+/cd56+ hematodermic neoplasm
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Elderly; Age of death: elderly;

Classifications:



External Ids:

Orphanet 59 ORPHA86870
ICD10 via Orphanet 34 C86.4
ICD10 33 C86.4
UMLS 73 C1301363

Summaries for Blastic Plasmacytoid Dendritic Cell

MalaCards based summary : Blastic Plasmacytoid Dendritic Cell, also known as blastic plasmacytoid dendritic cell neoplasm, is related to leukemia, acute myeloid and dendritic cell tumor. An important gene associated with Blastic Plasmacytoid Dendritic Cell is NCAM1 (Neural Cell Adhesion Molecule 1), and among its related pathways/superpathways are NF-kappaB Signaling and Cell adhesion molecules (CAMs). The drugs Trastuzumab and Adenosine have been mentioned in the context of this disorder. Affiliated tissues include nk cells, myeloid and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Blastic Plasmacytoid Dendritic Cell

Diseases related to Blastic Plasmacytoid Dendritic Cell via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 41)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 30.7 IL3RA MYB NCAM1 NPM1 TET2
2 dendritic cell tumor 11.3
3 leukemia 10.8
4 myeloid leukemia 10.6
5 chronic myelomonocytic leukemia 10.4
6 pdgfrb-associated chronic eosinophilic leukemia 10.4
7 leukemia, acute monocytic 10.3
8 myelodysplastic syndrome 10.3
9 hematopoietic stem cell transplantation 10.3
10 monocytic leukemia 10.3
11 ovarian serous adenofibroma 10.1 NCAM1 NR3C1
12 protoporphyria, erythropoietic, 1 10.1
13 retinoblastoma 10.1
14 anemia, autoimmune hemolytic 10.1
15 rheumatic fever-related antigen 10.1
16 xanthomatosis 10.1
17 basal cell carcinoma 1 10.1
18 acute leukemia 10.1
19 b-cell lymphomas 10.1
20 hemolytic anemia 10.1
21 post-transplant lymphoproliferative disease 10.1
22 cutaneous lupus erythematosus 10.1
23 lymphoma 10.1
24 sarcoma 10.1
25 rheumatic fever 10.1
26 melanoma 10.1
27 basal cell carcinoma 10.1
28 purpura 10.1
29 polyradiculopathy 10.1
30 mucormycosis 10.1
31 myeloid sarcoma 10.1
32 lupus erythematosus 10.1
33 macroglobulinemia 10.1
34 splenomegaly 10.1
35 acute basophilic leukemia 10.1 IL3RA MYB
36 diphtheria 10.1
37 peripheral t-cell lymphoma 10.0 NCAM1 TCL1A TET2
38 primary cutaneous diffuse large b-cell lymphoma, leg type 10.0 CDKN2A MYD88
39 hematologic cancer 9.8 CDKN1B IL3RA NCAM1 NPM1 NR3C1 TET2
40 precursor t-cell acute lymphoblastic leukemia 9.8 CDKN2A MYB TCL1A
41 localized osteosarcoma 9.8 CDKN2A CLEC4C

Graphical network of the top 20 diseases related to Blastic Plasmacytoid Dendritic Cell:



Diseases related to Blastic Plasmacytoid Dendritic Cell

Symptoms & Phenotypes for Blastic Plasmacytoid Dendritic Cell

GenomeRNAi Phenotypes related to Blastic Plasmacytoid Dendritic Cell according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.77 MYB
2 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.77 TCF4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.77 MYB
4 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.77 MYB
5 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.77 BRD4 IL3RA MYB TCF4
6 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.77 IL3RA
7 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.77 BRD4
8 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.77 MYB TCF4
9 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.77 MYB
10 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.77 MYB
11 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.77 MYB
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.77 MYB TCF4
13 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.77 IL3RA
14 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.77 BRD4 TCF4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.77 IL3RA TCF4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.77 TCF4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.77 MYB
18 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.77 TCF4
19 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.77 IL3RA
20 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.77 MYB
21 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.77 BRD4

MGI Mouse Phenotypes related to Blastic Plasmacytoid Dendritic Cell:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.21 CD4 CDKN1B CDKN2A MYB MYD88 NCAM1
2 hematopoietic system MP:0005397 10.1 CD4 CDKN1B CDKN2A IL3RA MYB MYD88
3 immune system MP:0005387 10.03 CD4 CDKN1B CDKN2A IL3RA MYB MYD88
4 endocrine/exocrine gland MP:0005379 9.97 CD4 CDKN1B CDKN2A MYB MYD88 NR3C1
5 digestive/alimentary MP:0005381 9.95 CD4 CDKN1B CDKN2A MYD88 NR3C1 PECAM1
6 mortality/aging MP:0010768 9.73 CD4 CDKN1B CDKN2A MYB MYD88 NCAM1
7 liver/biliary system MP:0005370 9.7 CDKN1B CDKN2A MYB NPM1 NR3C1 PECAM1
8 no phenotypic analysis MP:0003012 9.23 CD4 CDKN1B CDKN2A CLEC4C MYB MYD88

Drugs & Therapeutics for Blastic Plasmacytoid Dendritic Cell

Drugs for Blastic Plasmacytoid Dendritic Cell (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
2
Adenosine Approved, Investigational Phase 2 58-61-7 60961
3
Nivolumab Approved Phase 2 946414-94-4
4
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
5
Fludarabine Approved Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
6
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
7
Vidarabine Approved, Investigational Phase 2,Phase 1,Not Applicable 24356-66-9 32326 21704
8
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
9
Mycophenolic acid Approved Phase 2,Not Applicable 24280-93-1 446541
10
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 6055-19-2, 50-18-0 2907
11
leucovorin Approved Phase 2 58-05-9 6006 143
12
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
13
Idarubicin Approved Phase 2 58957-92-9 42890
14
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
16 Antineoplastic Agents, Phytogenic Phase 2
17 Maytansine Phase 2
18 Antimitotic Agents Phase 2
19 Ado-trastuzumab emtansine Phase 2
20 Antibodies, Monoclonal Phase 2
21 Immunoglobulins Phase 2,Phase 1
22 Immunologic Factors Phase 2,Phase 1,Not Applicable
23 Antibodies Phase 2,Phase 1
24 Folate Phase 2
25 Antitubercular Agents Phase 2,Not Applicable
26 Vidarabine Phosphate Phase 2,Phase 1,Not Applicable
27 Antineoplastic Agents, Alkylating Phase 2,Phase 1
28 Antiviral Agents Phase 2,Phase 1,Not Applicable
29 Vitamin B9 Phase 2
30 Calcineurin Inhibitors Phase 2,Not Applicable
31 Vitamin B Complex Phase 2
32 Antirheumatic Agents Phase 2,Phase 1,Not Applicable
33 Anti-Infective Agents Phase 2,Phase 1,Not Applicable
34 Alkylating Agents Phase 2,Phase 1
35 Antimetabolites Phase 2,Phase 1,Not Applicable
36 Folic Acid Antagonists Phase 2
37 Immunosuppressive Agents Phase 2,Phase 1,Not Applicable
38 Anti-Bacterial Agents Phase 2,Not Applicable
39 Antibiotics, Antitubercular Phase 2,Not Applicable
40 Antimetabolites, Antineoplastic Phase 2,Phase 1,Not Applicable
41 Dermatologic Agents Phase 2,Not Applicable
42 Nucleic Acid Synthesis Inhibitors Phase 2
43 Anti-Inflammatory Agents Phase 2
44 Antineoplastic Agents, Hormonal Phase 2
45 Topoisomerase Inhibitors Phase 2
46 Gastrointestinal Agents Phase 2
47 Autonomic Agents Phase 2
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
49 Peripheral Nervous System Agents Phase 2
50
asparaginase Phase 2

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00397579 Phase 1, Phase 2 DT388IL3
2 An Open-label Phase II Study of Lorvotuzumab Mertansine Completed NCT02420873 Phase 2 Lorvotuzumab Mertansine (IMGN901)
3 SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Recruiting NCT02113982 Phase 1, Phase 2 SL-401
4 Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Recruiting NCT03075553 Phase 2
5 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Recruiting NCT02220985 Phase 2 Cyclophosphamide;Fludarabine Phosphate;Methotrexate;Mycophenolate Mofetil;Tacrolimus;Thiotepa
6 Combination Chemotherapy in Patients With Newly Diagnosed BPDCN Not yet recruiting NCT03599960 Phase 2 Chemotherapy
7 Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Not yet recruiting NCT03739606 Phase 2
8 Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant Not yet recruiting NCT03779854 Phase 2 Thiotepa;Fludarabine;Cyclophosphamide;Busulfan;Tacrolimus;Methotrexate
9 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1 Akt inhibitor MK2206
10 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Recruiting NCT03485547 Phase 1 Venetoclax
11 Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN Recruiting NCT03203369 Phase 1
12 Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recruiting NCT02159495 Phase 1 cyclophosphamide;Fludarabine Phosphate
13 Study of IMGN632 in Patients With Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies Recruiting NCT03386513 Phase 1 IMGN632
14 PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies Recruiting NCT02730312 Phase 1
15 HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant Recruiting NCT03326921 Phase 1 Fludarabine Phosphate
16 Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Not yet recruiting NCT03807063 Phase 1 Rimiducid
17 Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN) Completed NCT02859623
18 Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Active, not recruiting NCT02652715 Not Applicable
19 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies Active, not recruiting NCT00014235 Not Applicable fludarabine phosphate;cyclosporine;mycophenolate mofetil

Search NIH Clinical Center for Blastic Plasmacytoid Dendritic Cell

Genetic Tests for Blastic Plasmacytoid Dendritic Cell

Anatomical Context for Blastic Plasmacytoid Dendritic Cell

MalaCards organs/tissues related to Blastic Plasmacytoid Dendritic Cell:

41
Nk Cells, Myeloid, Bone, T Cells, Bone Marrow, Skin, Monocytes

Publications for Blastic Plasmacytoid Dendritic Cell

Articles related to Blastic Plasmacytoid Dendritic Cell:

(show top 50) (show all 253)
# Title Authors Year
1
First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases. ( 29720227 )
2018
2
Benefit of electron beam therapy in combination with medium-dose systemic corticosteroid as a palliative treatment for elderly patients with blastic plasmacytoid dendritic cell neoplasm: case report and review of the literature. ( 29876950 )
2018
3
Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis. ( 29705980 )
2018
4
Clinicopathologic retrospective analysis of blastic plasmacytoid dendritic cell neoplasms. ( 29760611 )
2018
5
Detection of Minimal Bone Marrow involvement of Blastic Plasmacytoid Dendritic Cell Neoplastic Cells - CD303 immunostaining as a diagnostic tool. ( 29415975 )
2018
6
Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents. ( 29455234 )
2018
7
Immunophenotypic CD56 Variation Within a Single Patient With Blastic Plasmacytoid Dendritic Cell Neoplasm. ( 29490374 )
2018
8
Blastic plasmacytoid dendritic cell neoplasm: a rare case of gingival lesion with leukaemic presentation. ( 29735506 )
2018
9
Clonal evolution in the transition from cutaneous disease to acute leukaemia suggested by liquid biopsy in blastic plasmacytoid dendritic cell neoplasm. ( 29419438 )
2018
10
Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. ( 29795241 )
2018
11
Blastic plasmacytoid dendritic cell neoplasm with centrocyte-like morphology clinically simulating a melanocytic nevus. ( 29293270 )
2018
12
Blastic plasmacytoid dendritic cell neoplasm. ( 29636962 )
2018
13
Report On Three Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. ( 29666036 )
2018
14
Atypical presentation of blastic plasmacytoid dendritic cell neoplasm: A potential diagnostic pitfall in nasal cavity. ( 29884520 )
2018
15
8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms. ( 29407586 )
2018
16
Exploring the effect of chidamide on blastic plasmacytoid dendritic cell neoplasm: a case report and literature review. ( 29379294 )
2018
17
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis. ( 29080220 )
2018
18
Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations. ( 29411884 )
2018
19
An Analysis of Blastic Plasmacytoid Dendritic Cell Neoplasm with Translocations Involving the MYC Locus Identifies t(6;8)(p21;q24) as a Recurrent Cytogenetic Abnormality. ( 29884995 )
2018
20
Incidental diagnosis of blastic plasmacytoid dendritic cell neoplasm in skin excision for basal cell carcinoma. ( 30094841 )
2018
21
Skin lesions serve as clues to relapse of pediatric blastic plasmacytoid dendritic cell neoplasm. ( 29436012 )
2018
22
The distinctive cytology and disease evolution of blastic plasmacytoid dendritic cell neoplasm. ( 30020546 )
2018
23
A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm With Unusual Presentation. ( 30040070 )
2018
24
The advances in therapy of blastic plasmacytoid dendritic cell neoplasm. ( 30118336 )
2018
25
Blastic Plasmacytoid Dendritic Cell Neoplasm: Still an Enigma. ( 30127580 )
2018
26
Allogeneic Hematopoietic Cell Transplantation Is an Effective Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm in First Complete Remission: Systematic Review and Meta-analysis. ( 30145196 )
2018
27
Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. ( 30189324 )
2018
28
Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. ( 30190511 )
2018
29
Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events. ( 30248580 )
2018
30
An unexpected diagnosis: leukaemic presentation of blastic plasmacytoid dendritic cell neoplasm with massive splenomegaly. ( 30274817 )
2018
31
Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm. ( 30304659 )
2018
32
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community. ( 30338458 )
2018
33
Blastic Plasmacytoid Dendritic Cell Neoplasm. ( 30350260 )
2018
34
Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. ( 30381297 )
2018
35
Blastic plasmacytoid dendritic cell neoplasm with immunoblastoid morphology and MYC rearrangement and overexpression. ( 30482401 )
2018
36
Clinicopathological analysis of 46 cases with CD4+ and/or CD56+ immature hematolymphoid malignancy: reappraisal of blastic plasmacytoid dendritic cell and -related neoplasms. ( 28795410 )
2017
37
CD4-Negative Variant of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm With a Novel PBRM1 Mutation in an 11-Year-Old Girl. ( 28419186 )
2017
38
A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Extensively Studied by Flow Cytometry and Immunohistochemistry. ( 28409040 )
2017
39
BET Inhibitors Target Blastic Plasmacytoid Dendritic Cell Neoplasms. ( 27913389 )
2017
40
Blastic plasmacytoid dendritic cell leukemia in a black malian. ( 28656936 )
2017
41
Blastic plasmacytoid dendritic cell neoplasm in children: A review of two cases. ( 28856005 )
2017
42
Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Systematic Literature Review. ( 28906324 )
2017
43
Successful treatment with biweekly CHOP for bone marrow relapse of blastic plasmacytoid dendritic cell neoplasm. ( 28321093 )
2017
44
Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond. ( 29064022 )
2017
45
Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN. ( 29064025 )
2017
46
Blastic plasmacytoid dendritic cell neoplasm: a pathological illustration of two clinical cases. ( 28762083 )
2017
47
Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell neoplasm. ( 28344318 )
2017
48
Blastic Plasmacytoid Dendritic Cell Neoplasm Presenting as Erythematous Nodules with Gallbladder Involvement. ( 28761306 )
2017
49
Concomitant Occurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukaemia after Lenalidomide Treatment for. ( 28879716 )
2017
50
Blastic plasmacytoid dendritic cell neoplasm presenting as leukemia without cutaneous lesion. ( 29237977 )
2017

Variations for Blastic Plasmacytoid Dendritic Cell

Expression for Blastic Plasmacytoid Dendritic Cell

Search GEO for disease gene expression data for Blastic Plasmacytoid Dendritic Cell.

Pathways for Blastic Plasmacytoid Dendritic Cell

GO Terms for Blastic Plasmacytoid Dendritic Cell

Cellular components related to Blastic Plasmacytoid Dendritic Cell according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.26 CD4 IL3RA NCAM1 PECAM1
2 protein-containing complex GO:0032991 9.02 CDKN1B MYD88 NPM1 NR3C1 TCL1A

Biological processes related to Blastic Plasmacytoid Dendritic Cell according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.56 BRD4 CDKN2A MYB NPM1 NR3C1 SPIB
2 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.26 CDKN1B CDKN2A
3 positive regulation of transcription, DNA-templated GO:0045893 9.17 BRD4 CD4 CDKN2A MYB NPM1 SUPT3H
4 negative regulation of phosphorylation GO:0042326 9.16 CDKN1B CDKN2A

Molecular functions related to Blastic Plasmacytoid Dendritic Cell according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 core promoter binding GO:0001047 9.16 NPM1 NR3C1
2 protein kinase binding GO:0019901 9.1 CD4 CDKN1B CDKN2A NPM1 NR3C1 TCL1A
3 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.96 CDKN1B CDKN2A

Sources for Blastic Plasmacytoid Dendritic Cell

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....